Axxcess Wealth Management LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 89,792 shares of the company's stock after selling 7,438 shares during the quarter. Axxcess Wealth Management LLC's holdings in Johnson & Johnson were worth $14,891,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in JNJ. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson in the fourth quarter valued at $29,000. Conquis Financial LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at $33,000. Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson in the fourth quarter valued at $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in Johnson & Johnson in the fourth quarter valued at $38,000. 69.55% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Stock Down 0.5%
Shares of NYSE JNJ traded down $0.82 on Friday, hitting $156.87. The company had a trading volume of 7,866,488 shares, compared to its average volume of 8,066,975. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The business has a 50 day moving average of $153.75 and a two-hundred day moving average of $154.43. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $377.44 billion, a P/E ratio of 17.45, a PEG ratio of 2.15 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson's dividend payout ratio is presently 57.84%.
Analysts Set New Price Targets
Several equities analysts recently commented on the company. Bank of America dropped their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a research note on Thursday. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Finally, Barclays dropped their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $171.00.
View Our Latest Report on JNJ
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
